Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Control Bionics Ltd. ( (AU:CBL) ) is now available.
Control Bionics Limited reported a 26% decline in revenue to $2.82 million for the half-year ended 31 December 2025, alongside a sharp increase in net loss after tax to $3.61 million, compared with the prior corresponding period. No dividends were declared, but net tangible assets per share improved to 0.73 cents from 0.49 cents, indicating some balance sheet strengthening despite the deteriorating earnings performance.
The company gained full control of Neuro Elite Athletics, LLC on 31 December 2025, increasing its interest from 20.71% to 100% and transitioning the entity from an associate to a wholly owned subsidiary. While the acquisition did not materially affect the half-year loss due to its timing, the move consolidates Neuro Elite’s operations within the group and may influence future financial performance and strategic positioning in related neuro and performance markets.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
More about Control Bionics Ltd.
Control Bionics Limited operates in the medical technology sector, developing and supplying assistive communication and control devices for people with severe disabilities. The company focuses on neuro-based human–machine interfaces and related solutions, targeting healthcare, rehabilitation, and accessibility markets in which advanced assistive technologies are in demand.
Average Trading Volume: 488,307
Technical Sentiment Signal: Buy
Current Market Cap: A$25.13M
Learn more about CBL stock on TipRanks’ Stock Analysis page.